Form 4: Actinium Pharmaceuticals Director Cancels Stock Options
SEC Form 4 Filing
C. David Nicholson, a director at Actinium Pharmaceuticals, canceled several stock options effective March 31, 2025.
Summary
- On April 2, 2025, C. David Nicholson, a director of Actinium Pharmaceuticals, filed a Form 4.
- The form reports the cancellation of several stock options effective March 31, 2025.
- The stock options, with varying exercise prices and expiration dates, were canceled as per an Option Cancellation and Release Agreement.
- The cancellation was in exchange for nominal consideration.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option cancellations, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock option management, common in publicly traded companies.
Stakeholder Impact
- The cancellation of stock options may have a minor impact on the total number of outstanding options, potentially affecting shareholder dilution.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Effective date of stock option cancellations. |
| 04/02/2025 | Form 4 filing date. |
| 04/15/2026 | Earliest expiration date of canceled stock options. |
| 12/28/2033 | Latest expiration date of canceled stock options. |
Keywords
Actinium Pharmaceuticals, Stock Options, Form 4, Director, Cancellation, ATNM, Nicholson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.